CD8A and neoplasm: Upon binding, CD40–CD40L activates dendritic cells (DCs), macrophages, and B cells, enhancing their capacity to process and present tumor-associated antigens (TAAs) to cytotoxic CD8+ T-cells (Fig. 1A).